Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.
Christine NitschkeBenedikt MarkmannPhilipp WalterAnita BadbaranMarie TölleJolanthe KropidlowskiYassine BelloumMara R GoetzJan BardenhagenLouisa SternJoseph TintelnotMartin SchönleinMarianne SinnPaul van der LeestRonald SimonAsmus HeumannJakob R IzbickiKlaus PantelHarriet WikmanFaik G UzunogluPublished in: Clinical chemistry (2023)
KRAS ctDNA detection is an independent adverse prognostic marker in curative and palliative PDAC patients-at all sites of blood draw and a strong follow-up marker. The most substantial prognostic impact was seen for PV blood, which could be an effective novel tool for identifying prognostic borderline patients-guiding future decision-making on neoadjuvant treatment despite anatomical resectability. In addition, higher PV mutant copy numbers contribute to an improved technical feasibility.
Keyphrases
- end stage renal disease
- decision making
- wild type
- rectal cancer
- prognostic factors
- ejection fraction
- newly diagnosed
- chronic kidney disease
- loop mediated isothermal amplification
- real time pcr
- palliative care
- peritoneal dialysis
- circulating tumor
- locally advanced
- radiation therapy
- patient reported outcomes
- emergency department
- squamous cell carcinoma
- free survival
- drug induced
- cell free